Skip to main content

CRISPR Therapeutics AG

corporate_fare Company Profile

CRISPR Therapeutics AG

CRSP·NASDAQ·Life Sciences·CIK 0001674416

CRISPR Therapeutics AG is a biopharmaceutical company focused on developing gene-based medicines using CRISPR/Cas9 technology. This technology allows for the precise alteration of specific genomic DNA sequences. The company achieved the first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023, in collaboration with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG's therapeutic programs are organized into four core franchises: hemoglobinopathies, in vivo approaches, CAR T approaches, and regenerative medicine. The company employs either an ex vivo approach, editing cells outside the body before administration, or an in vivo editing approach, delivering the therapeutic directly to target cells within the body. In the hemoglobinopathies franchise, CASGEVY has received approval in the United States and other countries for treating eligible patients with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). Further research in this area, also with Vertex, includes targeted conditioning and in vivo editing of hematopoietic stem cells. The in vivo approaches franchise is developing a portfolio of programs for common and rare diseases, utilizing both in vivo editing and siRNA approaches. The CAR T franchise is advancing next-generation gene-edited cell therapy programs, including allogeneic chimeric antigen receptor T cell (CAR T) candidates for autoimmune indications and oncology. Lastly, the regenerative medicine franchise is developing a deviceless beta cell replacement product candidate, consisting of unencapsulated precursor islet cells derived from induced pluripotent stem cells, for the treatment of Type 1 diabetes (T1D).

CRISPR Therapeutics AG (NASDAQ:CRSP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for CRSP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for CRSP spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • CTX310 Cuts Triglycerides 63% at Day 30, Beating Analyst Expectations
  • CTX310 Cuts Triglycerides 63% at Day 30 in Severe Hypertriglyceridemia
  • CRISPR Q3: Net Loss $111.4M, $2.28B Cash, 24-Month Runway Confirmed
  • CRISPR Q3: CASGEVY Revenue $99M, Up 30% QoQ; CTX310 Wins Two RMAT Designations
  • CRISPR Therapeutics Posts $12.7M in Q3 Revenue

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.51M
Net Income
-$581.6M
Diluted EPS
-$6.47
Op. Cash Flow
-$345.01M
Free Cash Flow
-$345.93M
Operating Income
-$664.57M
Cash & Equivalents
$347.56M
Debt / Equity
0.00×
Net Margin
-165.70×
Shares Outstanding
95.89M sh
Source: 10-K · filed 2026-02-12 · accession 0001193125-26-048957

Short Interest & Short Volume

13.09 days to cover

FINRA reported short interest of 17,189,067 shares in CRSP as of the October 30, 2026 settlement, a 4.5% increase from the prior period — about 13.1 days to cover at its recent average daily volume. On November 20, 2026, 59.6% of CRSP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,189,067 shares as of October 30, 2026
Change vs prior period▲ 4.5%
Days to cover13.09 at avg daily volume of 1,312,645
Daily short volume (FINRA facilities)59.6% of 1,168,534 shares on November 20, 2026
5-day average short volume67.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CRSP, detected from its recent SEC filings · based on capital-structure filings through 2026-06-04.

New Equity Incentive Plan Approved · Capital Band Increase Authorized

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$39.5 +1.02% today
52-week range · as of 2026-11-02 $39.5 – $65.98
Market cap
$3.79B
Volume
3.3M (1.7× avg)
3-mo avg 1.9M
Live data · 2026-11-21 09:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRSP - Latest Insights

CRSP
Nov 10, 2026, 1:48 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $45.48
Real-time Price: $39.50 info
Change: -$5.98 (-13%) info
Market Cap: $3.793B info
CRSP
Nov 09, 2026, 9:16 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $50.42
Real-time Price: $39.50 info
Change: -$10.92 (-22%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.98
Real-time Price: $39.50 info
Change: -$10.48 (-21%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $39.50 info
Change: -$9.51 (-19%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:06 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $39.50 info
Change: -$9.51 (-19%) info
Market Cap: $3.793B info
CRSP
Oct 19, 2026, 4:30 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $49.00
Real-time Price: $39.50 info
Change: -$9.50 (-19%) info
Market Cap: $3.793B info
CRSP
Aug 03, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $50.70
Real-time Price: $39.50 info
Change: -$11.20 (-22%) info
Market Cap: $3.793B info
CRSP
Aug 03, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $50.70
Real-time Price: $39.50 info
Change: -$11.20 (-22%) info
Market Cap: $3.793B info
CRSP
Jun 04, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $57.00
Real-time Price: $39.50 info
Change: -$17.50 (-31%) info
Market Cap: $3.793B info
CRSP
May 13, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $52.75
Real-time Price: $39.50 info
Change: -$13.25 (-25%) info
Market Cap: $3.793B info
CRSP
May 04, 2026, 4:48 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $53.04
Real-time Price: $39.50 info
Change: -$13.54 (-26%) info
Market Cap: $3.793B info
CRSP
May 04, 2026, 4:41 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $53.04
Real-time Price: $39.50 info
Change: -$13.54 (-26%) info
Market Cap: $3.793B info
CRSP
May 04, 2026, 4:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $53.55
Real-time Price: $39.50 info
Change: -$14.05 (-26%) info
Market Cap: $3.793B info
CRSP
Apr 21, 2026, 8:11 AM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $58.00
Real-time Price: $39.50 info
Change: -$18.50 (-32%) info
Market Cap: $3.793B info
CRSP
Apr 21, 2026, 8:05 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $58.00
Real-time Price: $39.50 info
Change: -$18.50 (-32%) info
Market Cap: $3.793B info
CRSP
Apr 02, 2026, 4:23 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $49.30
Real-time Price: $39.50 info
Change: -$9.80 (-20%) info
Market Cap: $3.793B info
CRSP
Mar 16, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $48.95
Real-time Price: $39.50 info
Change: -$9.45 (-19%) info
Market Cap: $3.793B info
CRSP
Mar 11, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $51.25
Real-time Price: $39.50 info
Change: -$11.75 (-23%) info
Market Cap: $3.793B info
CRSP
Mar 11, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $53.00
Real-time Price: $39.50 info
Change: -$13.50 (-25%) info
Market Cap: $3.793B info
CRSP
Mar 10, 2026, 10:43 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $54.39
Real-time Price: $39.50 info
Change: -$14.89 (-27%) info
Market Cap: $3.793B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets